GSK agrees to acquire ChImagen therapy: what it means for GSK stock at $750 million
Published on 10/03/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On September 15, 2026, GSK plc announced an agreement to acquire a trispecific T-cell engager from ChImagen Biosciences for development in multiple myeloma, with a total potential value of up to $750 million, according to GSK.
At 11:52 a.m. CEST on October 3, 2026, Lang & Schwarz showed the stock at EUR 20.83 in weekend trading, unchanged at 0.00 percent versus the EUR 20.83 close at Lang & Schwarz on October 2, 2026.
Weekend trading
Lang & Schwarz listed a bid of EUR 20.71 and an ask of EUR 20.95 at the stated time. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of GSK stock.
ChImagen agreement
Under the agreement, GSK will receive full global rights to the T-cell-engager program. The company plans to develop and commercialize the asset for multiple myeloma, with the program expected to enter Phase I trials in 2027. ChImagen is eligible for success-based development and commercial milestone payments, bringing the agreement's total potential value to up to $750 million, according to GSK.
Last Xetra trading day
The EUR 20.83 close at Lang & Schwarz on October 2, 2026 provides the reference level for the weekend-trading price. The quoted euro price is separate from the dated company announcement.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
